id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15367 R63241 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Cognitive mean score ≤ 88 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.74 [0.49;28.29] C excluded (control group) |
2/21 2/73 | 4 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15368 R63254 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Cognitive mean score ≤ 88 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.42 [0.32;18.46] C | 2/21 2/48 | 4 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9937 R53391 |
Videman (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2016 | Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
1.00 [0.18;5.63] excluded (control group) |
-/9 -/8 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9936 R53392 |
Videman (Carbamazepine) (Controls unexposed, disease free), 2016 | Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 4.58 [1.25;16.81] | -/9 -/59 | - | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9732 R53388 |
Meador (Carbamazepine), 2013 | the Bayley Scales of Infant Development (BSID) <85 (at 2 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 2.36 [0.97;5.73] C | 15/48 11/68 | 26 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9695 R53385 |
Bromley (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Overall ability below average performance (≤ 84) (Griffiths) (mean age 10 months old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.16 [0.34;3.91] C excluded (control group) |
8/48 5/34 | 13 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9698 R53386 |
Bromley (Carbamazepine) (Controls unexposed, disease free), 2010 | Overall ability below average performance (≤ 84) (Griffiths) (mean age 10 months old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
2.36 [0.96;5.79] C excluded (control group) |
8/48 18/230 | 26 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9701 R53387 |
Bromley (Carbamazepine) (Controls unexposed, sick), 2010 | Overall ability below average performance (≤ 84) (Griffiths) (mean age 10 months old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.50 [0.49;12.74] C | 8/48 2/27 | 10 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9737 R53390 |
Thomas b (Carbamazepine), 2008 | Impaired Mental Development Quotient < 84 (The Developmental Assessment Scale (DAS II)) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.93 [0.39;2.20] C | 30/101 10/32 | 40 | 101 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9651 R53393 |
Wide (Carbamazepine), 2000 | Griffiths test total score (SD estimated) | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 0.34 [0.15;0.81] | -/35 -/35 | - | 35 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9639 R53389 |
Ornoy (Carbamazepine), 1996 | Mental developmental index (MDI) (Bayley) OR (general cognitive index (GCI) (McCarthy) score ≤80 | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 14.41 [0.77;269.27] C | 5/41 0/47 | 5 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 1.71 [0.73;4.01] | 85 | 303 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, disease free; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine; 6: Carbamazepine; 7: Carbamazepine;
Asymetry test p-value = 0.1336 (by Egger's regression)
slope=-1.2924 (0.9164); intercept=2.8100 (1.5705); t=1.7892; p=0.1336
excluded 9695, 9698, 9937, 15367